Method to determine outcome for patients with prostatic disease
First Claim
Patent Images
1. A method to determine the risk of progression of a prostate cancer patient after therapy, comprising:
- a) detecting or determining the amount or level of VEGF, UPAR, UPA, or sVCAM in a blood sample obtained from a patient prior to therapy for clinically localized prostate cancer; and
b) correlating the amount or level of VEGF, UPAR, UPA, or sVCAM with the risk of progression.
2 Assignments
0 Petitions
Accused Products
Abstract
A method for prognosis of patients with prostate cancer, e.g., clinically localized prostate cancer, is provided.
-
Citations
67 Claims
-
1. A method to determine the risk of progression of a prostate cancer patient after therapy, comprising:
-
a) detecting or determining the amount or level of VEGF, UPAR, UPA, or sVCAM in a blood sample obtained from a patient prior to therapy for clinically localized prostate cancer; and
b) correlating the amount or level of VEGF, UPAR, UPA, or sVCAM with the risk of progression. - View Dependent Claims (4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 26, 28, 64)
-
-
2. A method to determine the risk of progression of a prostate cancer patient after therapy, comprising:
-
a) detecting or determining the amount or level of TGF-β
1 and IL6sR or IL6 in a blood sample, and the Gleason score in a prostate sample, obtained from a patient prior to therapy for clinically localized prostate cancer; and
b) correlating the amount or level of TGF-β
1 and IL6sR or IL6 and the Gleason score in a prostate sample, with the risk of progression. - View Dependent Claims (20, 21, 22, 23, 24, 25, 27, 29, 30)
-
-
3. A method to determine the prognosis of a prostate cancer patient after therapy, comprising:
-
a) detecting or determining the amount or level of TGF-β
1 and IL6sR or IL6 in a blood sample, and the Gleason score in a prostate sample, obtained from a patient prior to therapy for clinically localized prostate cancer; and
b) correlating the amount or level of TGF-β
1 and IL6sR or IL6 and the Gleason score in a prostate sample with the risk of non-prostate confined disease.
-
-
31. An apparatus, comprising:
-
a data input means, for input of test information comprising the level or amount of VEGF, UPAR, UPA, or sVCAM, in one or more samples obtained from a mammal;
a processor, executing a software for analysis of the level or amount of VEGF, UPAR, UPA, or sVCAM, in the one or more samples;
wherein the software analyzes the level or amount of VEGF, UPAR, UPA, or sVCAM, in the one or more samples and provides the risk of prostate disease progression in the mammal. - View Dependent Claims (35, 36, 65)
-
-
32. An apparatus, comprising:
-
a data input means, for input of test information comprising the level or amount of UPAR or UPA in one or more samples obtained from a mammal;
a processor, executing a software for analysis of the level or amount of UPAR or UPA in the one or more samples;
wherein the software analyzes the level or amount of UPAR or UPA in one or more samples and provides the risk of non-prostate confined disease in the mammal.
-
-
33. An apparatus, comprising:
-
a data input means, for input of test information comprising the level or amount of TGF-β
1 and IL6sR or IL6, and the Gleason score, in one or more samples obtained from a mammal;
a processor, executing a software for analysis of the level or amount of TGF-β
1 and IL6sR or IL6, and the Gleason score, in the one or more samples;
wherein the software analyzes the level or amount of TGF-β
1 and IL6sR or IL6, and the Gleason score, in the one or more samples and provides the risk of prostate disease progression in the mammal. - View Dependent Claims (37, 38)
-
-
34. An apparatus, comprising:
-
a data input means, for input of test information comprising the level or amount of TGF-β
1 and IL6sR or IL6, and the Gleason score, in one or more samples obtained from a mammal;
a processor, executing a software for analysis of the level or amount of TGF-β
1 and IL6sR or IL6, and the Gleason score, in the one or more samples;
wherein the software analyzes the level or amount of TGF-β
1 and IL6sR or IL6, and the Gleason score, in one or more samples and provides the risk of non-prostate confined disease in the mammal.
-
-
39. A method to determine the prognosis of a prostate cancer patient after therapy, comprising:
-
a) inputting test information to a data input means, wherein the information comprises the level or amount of VEGF, UPAR, UPA, or sVCAM, in one or more samples obtained from a prostate cancer patient;
b) executing a software for analysis of the test information; and
c) analyzing the test information so as to provide the risk of disease progression or non-prostate confined disease in the patient.
-
-
40. A method to determine the prognosis of a prostate cancer patient after therapy, comprising:
-
a) inputting test information to a data input means, wherein the information comprises the level or amount of TGF-β
1 and IL6sR or IL6, and the Gleason score, in one or more samples obtained from a prostate cancer patient;
b) executing a software for analysis of the test information; and
c) analyzing the test information so as to provide the risk of disease progression or non-prostate confined disease in the patient.
-
-
41. A method for predicting a probability of recurrence of prostatic cancer in a patient following radical prostatectomy, comprising:
-
a) correlating a set of pre-operative factors for the patient to a functional representation of a set of pre-operative factors determined for each of a plurality of persons previously diagnosed with prostatic cancer and having been treated by radical prostatectomy, so as to yield a value for total points for the patient, which set of factors for each of a plurality of persons is correlated with the incidence of recurrence of prostatic cancer for each person in the plurality of persons, wherein the set of pre-operative factors comprises pre-treatment TGF-β
1 level, pre-treatment IL6sR or IL6 level, and optionally one or more of pre-treatment PSA level, primary Gleason grade or secondary Gleason grade, wherein the functional representation comprises a scale for each of pre-treatment TGF-β
1 level, pre-treatment IL6sR or IL6 level, and optionally a scale for one or more of pre-treatment PSA level, primary Gleason grade or secondary Gleason grade, a points scale, a total points scale, and a predictor scale, wherein the scales for pre-treatment TGF-β
1 level, pre-treatment IL6sR or IL6 level, and optionally one or more of pre-treatment PSA level, primary Gleason grade or secondary Gleason grade, each have values on the scales which can be correlated with values on the points scale, and wherein the total points scale has values which may be correlated with values on the predictor scale; and
b) correlating the value on the total points scale for the patient with a value on the predictor scale to predict the quantitative probability of recurrence of prostatic cancer in the patient following radical prostatectomy. - View Dependent Claims (42, 43, 44, 45, 46, 47, 48, 49, 50)
-
-
51. An apparatus for predicting a probability of disease recurrence in a patient with prostatic cancer following a radical prostatectomy, which apparatus comprises:
-
a) a correlation of a set of pre-operative factors for each of a plurality of persons previously diagnosed with prostatic cancer and having been treated by radical prostatectomy with the incidence of recurrence of prostatic cancer for each person of the plurality of persons, wherein the set of pre-operative factors comprises pre-treatment TGF-β
1 level, pre-treatment IL6sR or IL6 level, and optionally one or more of pre-treatment PSA level, primary Gleason grade or secondary Gleason grade; and
b) a means for comparing an identical set of pre-operative factors determined from a patient diagnosed as having prostatic cancer to the correlation to predict the quantitative probability of recurrence of prostatic cancer in the patient following radical prostatectomy.
-
-
52. A nomogram for the graphic representation of a quantitative probability that a patient with prostate cancer will remain free of disease following radical prostatectomy, comprising:
- a plurality of scales and a solid support, the plurality of scales being disposed on the support and comprising a scale for each of pre-treatment TGF-β
1 level, pre-treatment IL6sR or IL6 level, and optionally one or more of pre-treatment PSA level, primary Gleason grade or secondary Gleason grade, a points scale, a total points scale and a predictor scale, wherein the scales for pre-treatment TGF-β
1 level, pre-treatment IL6sR or IL6 level, and optionally the scales for one or more of the pre-treatment PSA level, primary Gleason grade or secondary Gleason grade each has values on the scales, and wherein the scales for pre-treatment TGF-β
1 level, pre-treatment IL6sR or IL6 level, and optionally the scales for one or more of pre-treatment PSA level, primary Gleason grade or secondary Gleason grade are disposed on the solid support with respect to the points scale so that each of the values on the pre-treatment TGF-β
1 level, pre-treatment IL6sR or IL6 level, and optionally the one or more of the pre-treatment PSA level, primary Gleason grade or secondary Gleason grade can be correlated with values on the points scale, wherein the total points scale has values on the total points scale, and wherein the total points scale is disposed on the solid support with respect to the predictor scale so that the values on the total points scale may be correlated with values on the predictor scale, such that the values on the points scale correlating with the patient'"'"'s pre-treatment TGF-β
1 level, pre-treatment IL6sR or IL6 level, and optionally one or more of pre-treatment PSA level, primary Gleason grade or secondary Gleason grade can be added together to yield a total points value, and the total points value can be correlated with the predictor scale to predict the quantitative probability of recurrence. - View Dependent Claims (53, 54, 66)
- a plurality of scales and a solid support, the plurality of scales being disposed on the support and comprising a scale for each of pre-treatment TGF-β
-
55. An apparatus for predicting a probability of disease recurrence in a patient with prostatic cancer following a radical prostatectomy, which apparatus comprises:
- a scale for each of pre-treatment TGF-β
1 level, pre-treatment IL6sR or IL6 level, and optionally one or more of pre-treatment PSA level, primary Gleason grade or secondary Gleason grade, a points scale, a total points scale and a predictor scale, wherein the scales for pre-treatment TGF-β
1 level, pre-treatment IL6sR or IL6 level, and optionally the scales for one or more of pre-treatment PSA level, primary Gleason grade or secondary Gleason grade each has values on the scales, and wherein the scales for pre-treatment TGF-β
1 level, pre-treatment IL6sR or IL6 level, and optionally the scales for one or more of pre-treatment PSA level, primary Gleason grade or secondary Gleason grade are disposed so that each of the values on the pre-treatment TGF-β
1 level, pre-treatment IL6sR or IL6 level, and optionally the one or more of the pre-treatment PSA level, primary Gleason grade or secondary Gleason grade, can be correlated with values on the points scale, wherein the total points scale has values on the total points scale, and wherein the total points scale is disposed on the solid support with respect to the predictor scale so that the values on the total points scale may be correlated with values on the predictor scale, such that the values on the points scale correlating with the patient'"'"'s pre-treatment TGF-β
1 level, pre-treatment IL6sR or IL6 level, and optionally one or more of pre-treatment PSA level, primary Gleason grade or secondary Gleason grade can be added together to yield a total points value, and the total points value can be correlated with the predictor scale to predict the quantitative probability of recurrence.
- a scale for each of pre-treatment TGF-β
-
56. A method to determine the risk of progression of a prostate cancer patient after therapy, comprising:
-
a) providing i) the amount or level of TGF-β
1 in a blood plasma sample obtained from the patient after therapy;
ii) pathological Gleason score; and
iii) and optionally the amount or level of one or more of IL6sR, IL6 or PSA in a blood sample obtained from the patient prior to therapy; and
b) correlating the amount or level of post-treatment TGF-β
1, pathological Gleason score and optionally the amount or level of one or more of pre-treatment IL6sR, IL6 or PSA, with the risk of progression.
-
-
57. An apparatus, comprising:
-
a data input means, for input of test information comprising the level or amount of post-treatment TGF-β
1, pathological Gleason score, and optionally level or amount of one or more of pre-treatment IL6sR, IL6 or PSA, in one or more samples obtained from a mammal;
a processor, executing a software for analysis of the level or amount of post-treatment TGF-β
1, pathological Gleason score, and optionally level or amount of one or more of pre-treatment IL6sR, IL6 or PSA in the one or more samples;
wherein the software analyzes the level or amount of post-treatment TGF-β
1, pathological Gleason score, and optionally level or amount of one or more of pre-treatment IL6sR, IL6 or PSA in the one or more samples and provides the risk of prostate disease progression in the mammal.
-
-
58. A method to determine the prognosis of a prostate cancer patient after therapy, comprising:
-
a) inputting test information to a data input means, wherein the information comprises the level or amount of post-treatment TGF-β
1, pathological Gleason score, and optionally level or amount of one or more of pre-treatment IL6sR, IL6 or PSA, samples obtained from a prostate cancer patient;
b) executing a software for analysis of the test information; and
c) analyzing the test information so as to provide the risk of disease progression or non-prostate confined disease in the patient.
-
-
59. A method for predicting a probability of recurrence of prostatic cancer in a patient following radical prostatectomy, comprising:
-
a) correlating a set of factors for the patient to a functional representation of a set of factors determined for each of a plurality of persons previously diagnosed with prostatic cancer and having been treated by radical prostatectomy so as to yield a value for total points for the patient, which set of factors for each of a plurality of persons is correlated with the incidence of recurrence of prostatic cancer for each person in the plurality of persons, wherein the set of factors comprises post-treatment TGF-β
1 level, pathological Gleason score and optionally one or more of pre-treatment IL6sR, IL6 or PSA level, wherein the functional representation comprises a scale for each of post-treatment TGF-β
1 level, pathological Gleason score, and optionally one or more of pre-treatment IL6sR or IL6 or PSA level, a points scale, a total points scale, and a predictor scale, wherein the scales for post-treatment TGF-β
1 level, pathological Gleason score, and optionally one or more of pre-treatment IL6sR, IL6 or PSA level each have values on the scales which can be correlated with values on the points scale, and wherein the total points scale has values which may be correlated with values on the predictor scale; and
b) correlating the value on the total points scale for the patient with a value on the predictor scale to predict the quantitative probability of recurrence of prostatic cancer in the patient following radical prostatectomy.
-
-
60. An apparatus for predicting a probability of disease recurrence in a patient with prostatic cancer following a radical prostatectomy, which apparatus comprises:
-
a) a correlation of a set of factors for each of a plurality of persons previously diagnosed with prostatic cancer and having been treated by radical prostatectomy with the incidence of recurrence of prostatic cancer for each person of the plurality of persons, wherein the set of factors comprises post-treatment TGF-β
1 level, pathological Gleason, and optionally one or more of pre-treatment IL6sR, IL6 or PSA level; and
b) a means for comparing an identical set of factors determined from a patient diagnosed as having prostatic cancer to the correlation to predict the quantitative probability of recurrence of prostatic cancer in the patient following radical prostatectomy.
-
-
61. A nomogram for the graphic representation of a quantitative probability that a patient with prostate cancer will remain free of disease following radical prostatectomy, comprising:
- a plurality of scales and a solid support, the plurality of scales being disposed on the support and comprising a scale for each of post-treatment TGF-β
1 level, pathological Gleason score and optionally one or more of pre-treatment IL6sR, IL6 or PSA level, a points scale, a total points scale and a predictor scale, wherein the scales for post-treatment TGF-β
1 level, pathological Gleason score, and optionally one or more of pre-treatment IL6sR, IL6 or PSA level, each has values on the scales, and wherein the scales for post-treatment TGF-β
1 level, pathological Gleason score and optionally one or more of pre-treatment IL6sR, IL6 or PSA level are disposed on the solid support with respect to the points scale so that each of the values on the post-treatment TGF-β
1 level, pathological Gleason score and optionally one or more of pre-treatment IL6sR, IL6 or PSA level can be correlated with values on the points scale, wherein the total points scale has values on the total points scale, and wherein the total points scale is disposed on the solid support with respect to the predictor scale so that the values on the total points scale may be correlated with values on the predictor scale, such that the values on the points scale correlating with the patient'"'"'s post-treatment TGF-β
1 level, pathological Gleason score and optionally one or more of pre-treatment IL6sR, IL6 or PSA level, can be added together to yield a total points value, and the total points value can be correlated with the predictor scale to predict the quantitative probability of recurrence. - View Dependent Claims (62)
- a plurality of scales and a solid support, the plurality of scales being disposed on the support and comprising a scale for each of post-treatment TGF-β
-
63. An apparatus for predicting a probability of disease recurrence in a patient with prostatic cancer following a radical prostatectomy, which apparatus comprises:
- a scale for each of post-treatment TGF-β
1 level, pathological Gleason score and optionally one or more of pre-treatment IL6sR, IL6 or PSA level, a points scale, a total points scale and a predictor scale, wherein the scales for post-treatment TGF-β
1 level, pathological Gleason score, and optionally one or more of pre-treatment IL6sR, IL6 or PSA level, each has values on the scales, and wherein the scales for post-treatment TGF-β
1 level, pathological Gleason score and optionally one or more of pre-treatment IL6sR, IL6 or PSA level are disposed with respect to the points scale so that each of the values on the post-treatment TGF-β
1 level, pathological Gleason score and optionally one or more of pre-treatment IL6sR, IL6 or PSA level can be correlated with values on the points scale, wherein the total points scale has values on the total points scale, and wherein the total points scale is disposed with respect to the predictor scale so that the values on the total points scale may be correlated with values on the predictor scale, such that the values on the points scale correlating with the patient'"'"'s post-treatment TGF-β
1 level, pathological Gleason score and optionally one or more of pre-treatment IL6sR, IL6 or PSA level, can be added together to yield a total points value, and the total points value can be correlated with the predictor scale to predict the quantitative probability of recurrence.
- a scale for each of post-treatment TGF-β
-
67. A method to determine the risk of progression of a prostate cancer patient after therapy, comprising:
-
a) providing i) the amount or level of TGF-β
1 in a blood plasma sample obtained from a patient prior to therapy;
ii) the amount or level of IL6sR or IL6 in a blood sample obtained from a patient prior to therapy; and
iii) the Gleason score in a prostate sample; and
b) correlating the amount or level of TGF-β
1 and IL6sR or IL6 and the Gleason score in a prostate sample with the risk of non-prostate confined disease.
-
Specification